The study of canine atopic dermatitis involving the isolation of dogs

Fujimura, Masato

doi:10.2478/v10181-011-0041-8

Cited by 7 publications

(7 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Basis for such recommendations: There is still only one uncontrolled study that reported the benefit of house dust mite control with a benzyl benzoate acaricidal spray (Acarosan Spray, Bissell) for reduction of clinical signs of AD in mite-hypersensitive atopic dogs (QOE 2) [ 32 ]. Recently, the isolation of dogs with AD in cages in which house dust mites were controlled was shown to lead to a rapid reduction in pruritus in most dogs with IgE hypersensitivity to environmental allergens (QOE 2) [ 33 ]. B.1.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

et al. 2015

View full text Add to dashboard Cite

BackgroundIn 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document.ResultsThe treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD.ConclusionsThis first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0514-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Recently, the isolation of dogs with AD in cages in which house dust mites were controlled was shown to lead to a rapid reduction in pruritus in most dogs with IgE hypersensitivity to environmental allergens (QOE 2) [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that ALD constitutes 14 to 25% of CAD, which is similar to that of intrinsic AD in humans (20%) (Tokura 2010, Fujimura 2011, Kabashima et al 2013, Kawano et al 2013, Suto et al 2014. From what we know of the mode of action of CsA, it may be more effective against intrinsic AD, because IL-2 is a Th1 related cytokine and intrinsic AD in humans is Th1-dominant.…”

Section: Discussionmentioning

confidence: 81%

Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study

Fujimura¹,

Ishimaru²

2016

Polish Journal of Veterinary Sciences

Self Cite

View full text Add to dashboard Cite

In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79±29, POST:77±28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61±42, POST: 32±25, p<0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor.

show abstract

“…An interesting study evaluating the effect of 2-week isolation in 27 dogs with clinical diagnosis of AD showed that 63% of them improved while the rest did not. 42 The improvement was considered most likely due to the allergen avoidance in the hospital environment without furniture and carpets. Among the remaining 37%, 14% (4/27) of these dogs had a negative intradermal allergy testing for all environmental antigens.…”

Section: Intrinsic Ad or Atopic-like Dermatitismentioning

confidence: 99%

An update on the treatment of canine atopic dermatitis

Marsella¹

2012

VMRR

View full text Add to dashboard Cite

Remarkable progress has been made in recent years concerning our understanding of the pathogenesis of canine atopic dermatitis (AD). As our understanding improves, the therapeutic approach evolves. Of utmost importance is the documentation of skin barrier impairment in canine AD: ceramides deficiency leads to increased permeability and increased allergen penetration and sensitization. It is currently unknown whether this dysfunction is primary and genetically inherited or secondary to inflammation but it is accepted that skin barrier deficiency plays an important role in either starting or minimally exacerbating canine AD. Thus, the therapeutic approach has changed from focusing on the control of the inflammation to a combined approach that includes therapies aimed at skin barrier repair. The issue of skin barrier repair has been addressed both with oral administration of essential fatty acids and the topical application of products containing a combination of ceramides and fatty acids. These strategies are most helpful as adjunctive treatments and would be best used in young patients that have not developed chronic skin changes. Importantly, treatment for canine AD is multimodal and tailored to the individual patient, the age, and the duration of the disease. Client education plays an important role in explaining the importance of a long-term approach to minimize flare-ups and, in this context, topical therapy to correct skin barrier can be of great benefit. This is an area still in infancy and much work is needed to identify the best formulation. In human medicine, long-term use of moisturizers can have a profound effect on skin barrier and gene expression of proteins involved in skin barrier. This effect is variable depending on the formulation used. It is reasonable to speculate that the same may be true in dogs; thus, it is very important to identify the correct ingredients and formulation to use.

show abstract

The study of canine atopic dermatitis involving the isolation of dogs

Cited by 7 publications

References 11 publications

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study

An update on the treatment of canine atopic dermatitis

Contact Info

Product

Resources

About